Background Vandetanib added to cisplatin and radiation (RT) overcomes chemo RT and EGFR inhibitor resistance in head and neck squamous cell PIK-93 carcinoma (HNSCC) lines and models. grade ≥3 AEs were dysphagia (30%) stomatitis (33%) and mucosal swelling (27%). PIK-93 Five individuals discontinued vandetanib due to AEs. Conclusions Vandetanib with chemo RT PIK-93 was feasible.… Continue reading Background Vandetanib added to cisplatin and radiation (RT) overcomes chemo RT